Aetna considers allogeneic hematopoietic cell transplantation medically necessary for the treatment of severe aplastic anemia, Diamond-Blackfan anemia, Fanconi's anemia, paroxysmal nocturnal hemoglobinuria, and pure red cell aplasia when members meet the transplanting institution's selection criteria.
In the absence of a institution's selection criteria, Aetna considers allogeneic hematopoietic cell transplantation medically necessary for the treatment of severe aplastic anemia when the member has at least 3 of the 4 following features:
In the absence of an institution's selection criteria, Aetna considers allogeneic hematopoietic cell transplantation medically necessary for the treatment of Diamond-Blackfan anemia in persons who are refractory to corticosteroids.
In the absence of an institution's selection criteria, Aetna considers allogeneic hematopoietic cell transplantation medically necessary for Fanconi's anemia in persons with severe bone marrow failure, myelodysplastic syndrome, or acute myelogenous leukemia.
In the absence of an institution's selection criteria, Aetna considers allogeneic hematopoietic cell transplantation medically necessary in persons with paroxysmal nocturnal hemoglobinuria with ongoing transfusion requirements and a suitable HLA-matched donor.
In the absence of a institution's selection criteria, Aetna considers allogeneic hematopoietic cell transplantation medically necessary for the treatment of pure red cell aplasia when the criteria for the treatment of severe aplastic anemia listed above are met.
Aetna considers autologous hematopoietic cell transplantation experimental and investigational for the treatment of severe aplastic anemia, Diamond-Blackfan anemia, Fanconi's anemia, paroxysmal nocturnal hemoglobinuria, and pure red cell aplasia because its effectiveness for these indications has not been established.Background
Aplastic anemia (AA) is characterized by peripheral blood pancytopenia, resulting from a failure of the bone marrow to produce blood cells. In the United States, it has an age-adjusted incidence of 2.2 per million populations per year. Pathogenic mechanisms for AA vary and include intrinsic defects of hematopoietic stem cells, defects in the marrow micro-environment, and abnormal humoral or cellular immune control of hematopoiesis. In most patients, AA is of unknown etiology (idiopathic), whereas in some, the disease can be secondary to infections, drugs or toxin exposure, and hereditary causes (e.g., Fanconi's anemia or Diamond-Blackfan syndrome). Severe AA is defined by the presence of neutrophils less than 0.5 x 109/L, platelets less than 20 x 109/L, reticulocytes less than 1 %, and bone marrow cellularity less than 20 %. When 3 of 4 of these symptoms are present, the median survival without therapy is about 3 months, with only 20 % of patients surviving for 12 months. Currently, 2 definitive treatments are available for patients with severe AA: (i) immuno-suppressive therapy (IST) that includes the use of anti-thymocyte globulin, cyclosporine, and cyclophosphamide; and (ii) allogeneic bone marrow transplantation (ABMT). The benefits of each are comparable. However, certain subsets of patients derive superior benefit from one or the other.
Allogeneic bone marrow transplantation from human leukocyte antigen (HLA)-matched, related donors is generally accepted as the initial treatment of choice for young patients (less than 20 years old). It results in the complete reconstitution of hematopoiesis, whereas autologous hematopoietic remissions after IST are more susceptible to relapse. The literature indicates that survival rates after ABMT, in patients between the ages of 20 and 40, are comparable to those reported for IST. Better survival rates after ABMT have been attained with improved conditioning regimens and graft-versus-host disease (GVHD) prophylaxis. Best current results demonstrate long-term, event-free survivals with successful allografts on the order of 90 %. Long-term complications after ABMT include GVHD and secondary neoplasms. The role of ABMT from an unrelated donor is being investigated.
For patients older than 40, the generally accepted treatment of choice is IST, which entails the combination of anti-thymocyte globulin and cyclosporin A. A variable proportion of patients (ranging from 20 to 80 %) respond to IST. However, although responses may be frequent, long-term outcome is guarded because some patients may relapse and others may develop a clonal disorder, including myelodysplasia, leukemia, or paroxysmal nocturnal hemoglobinuria. Long-term complications of IST include recurrence and development of clonal myeloid disorders.
In a review on ABMT for the treatment of AA, Horowitz (2000) stated that long-term survival rates ranged from less than 40 to more than 90 % in reported series. These rates have improved over the past 20 years due to significant reductions in GVHD, interstitial pneumonitis, and early transplant-related mortality. Most long-term survivors have excellent performance status. Late complications such as cataracts, thyroid disorders, joint problems, and therapy-related cancers are observed, especially in patients who received radiation for pre-transplant conditioning. Results are best in young patients transplanted with bone marrow from a HLA-identical sibling; early transplantation is appropriate in this group. For older patients or those without an HLA-identical related donor, transplants are better reserved for those who fail to respond to IST.
Kojima and co-workers (2000a) compared the long-term outcome of acquired AA in children treated with IST or ABMT. They recommended ABMT as first-line therapy in pediatric severe AA patients with an HLA-matched family donor. Alternative donor ABMT was recommended as salvage therapy in patients who relapsed or did not respond to initial IST. In a Consensus Conference on the Treatment of Aplastic Anemia, the participants recommended that the number of courses of IST for non-responders before unrelated ABMT consideration to be 1 for children and 2 for adults (Kojima et al, 2000b).
Bone marrow failure (BMF) syndromes entail a broad group of diseases of varying etiologies, in which hematopoeisis is abnormal or completely arrested in one or more cell lines. Bone marrow failure syndromes can be an acquired AA or can be congenital, as part of such syndromes as Fanconi anemia (FA), Diamond Blackfan anemia (DBA), and Schwachman Diamond syndrome. Hematopoietic bone marrow/stem cell transplantation is a therapeutic option for patients with BMF syndromes (Steele et al, 2006, Myers and Davies, 2009, Mehta et al, 2010).
In a report from the Aplastic Anemia Committee of the Japanese Society of Pediatric Hematology on hematopoietic stem cell transplantation (HSCT) for DBA, Mugishima et al (2007) stated that transfusion-dependent DBA patients opt for allogeneic HSCT as curative therapy. These investigators analyzed clinical outcomes of 19 transplanted Japanese patients. Prior to HSCT, 10 patients (53 %) suffered hemosiderosis with organ dysfunction, and all 8 with short stature (42 %) had adverse effects of prednisolone. Median age at the time of HSCT was 56 months. Transplantation sources were 13 bone marrow (6 HLA-matched siblings, and 6 HLA-matched and 1 HLA-mismatched unrelated donors), 5 cord blood (2 HLA-matched siblings and 3 HLA-mismatched unrelated donors), and 1 peripheral blood from haploidentical mother. All 13 patients with BMT and 2 with sibling cord blood transplantation (CBT) had successful engraftment. Of 3 patients who underwent unrelated CBT, 1 died after engraftment, and the other 2 had graft failure but succeeded in a second BMT from an HLA-disparate father and unrelated donor, respectively. One died shortly after haploidentical PBSCT. The 5-year failure-free survival rate after BMT was higher than CBT (100 %: 40 %, p = 0.002). Platelet recovery was slower in 7 unrelated BMT than in 6 sibling BMT (p = 0.030). No other factors were associated with engraftment and survival. These results suggested that allogeneic BMT, but not unrelated CBT, is an effective HSCT for refractory DBA.
In a report from the Italian pediatric group, Locatelli and colleagues (2007) noted that HSCT represents the only treatment potentially able to prevent/rescue the development of marrow failure and myeloid malignancies in patients with FA. While in the past HSCT from an HLA-identical sibling was proven to cure many patients, a higher incidence of treatment failure has been reported in recipients of an unrelated donor (UD) or HLA-partially matched related allograft. These researchers analyzed the outcome of 64 FA patients (age range of 2 to 20 years) who underwent HSCT between January 1989 and December 2005. Patients were transplanted from either an HLA-identical sibling (n = 31), an UD (n = 26), or an HLA-partially matched relative (n = 7). T-cell depletion of the graft was performed in patients transplanted from an HLA-disparate relative. The 8-year estimate of overall survival (OS) for the whole cohort was 67 %; it was 87 %, 40 % and 69 % when the donor was an HLA-identical sibling, an UD, and a mis-matched relative, respectively (p < 0.01). The outcome of recipients of grafts from an UD improved over time, the probability of survival being 10 % and 72 % for patients transplanted before and after 1998, respectively (p < 0.05). The OS probability of children who did or did not receive fludarabine in preparation for the allograft was 86 % and 59 %, respectively (p < 0.05). These data provided support to the concept that a relevant proportion of FA patients undergoing HSCT can now be successfully cured, even in the absence of an HLA-identical sibling, especially if the conditioning regimen includes fludarabine.
Roth and colleagues (2009) stated that paroxysmal nocturnal hemoglobinuria (PNH) is characterized by the clinical triad of corpuscular hemolytic anemia, thrombophilia, and cytopenia. This is caused by an acquired mutation of the PIG (phosphatidylinositol glycan)-A gene of the pluripotent hematopoetic stem cell. This results in a deficiency of GPI (glycosylphosphatidylinositol)-anchors and GPI-anchored proteins on the surface of affected blood cells. Flow cytometry is the standard for diagnosis and measurement of type and size of the PNH clone. Treatment of PNH is mainly symptomatic. Allogeneic BMT is the only curative option in case of severe complications during the course of the diseases.
Li and colleagues (2013) noted that although high-dose cyclophosphamide seems to achieve durable complete remission, there are still concerns about its too much early toxicity. Thus, these researchers designed a clinical study to examine the effects of high-dose cyclophosphamide/anti-thymocyte globulin (ATG) combined with cord blood infusion as first-line therapy for patients with severe AA. Between January 2003 and September 2007, these investigators treated 16 treatment-naive patients with severe AA with cord blood infusion after high-dose cyclophosphamide (50 mg/kg/day × 2) and rabbit ATG (3 mg/kg/day × 5) therapy. Although only 1 patient had durable full donor engraftment, 14 of the enrolled 16 patients had rapid autologous hematopoietic recovery. The median recovery time for neutrophils and platelets was only 23 and 37 days after infusion of cord blood. Of the 15 responding patients, all patients achieved treatment-free remission: 9 patients met the criteria for a complete remission; 6 patients achieved a partial remission. The authors concluded that infusion of cord blood after high-dose cyclophosphamide/ATG resulted in a rapid autologous hematologic recovery and a high response rate in patients with treatment-naive patients with severe AA. They stated that these promising results merit further investigation and confirmation on a larger number of patients.
An UpToDate review on “Aplastic anemia: Prognosis and treatment” (Schrier, 2013) states that “Only a fraction of patients with severe aplastic anemia in first or second complete remission are able to mobilize sufficient stem cells to undergo autologous hematopoietic cell transplantation (HCT). Accordingly, patients with relapsing or resistant disease, who have even fewer mobilizable stem cells than those in remission, are not candidates for autologous HCT". Furthermore, an UpToDate review on “Hematopoietic cell transplantation in aplastic anemia” (Negrin, 2013) recommends the use of allogeneic HCT; it does not mention the use of autologous HCT as a therapeutic option.
UpToDate reviews on “Hematopoietic cell transplantation for Diamond-Blackfan anemia and the myelodysplastic syndromes in children” (Khan, 2013) and “Hematopoietic cell transplantation for idiopathic severe aplastic anemia and Fanconi anemia in children” (Khan and Negrin, 2013) do not mention the use of autologous HCT as a therapeutic option.
An UpToDate review on “Diagnosis and treatment of paroxysmal nocturnal hemoglobinuria” (Rosse, 2013) states that “autologous transplantation is unlikely to be successful because of the difficulty in obtaining sufficient numbers of normal stem cells”.
In a Cochrane review, Peinemann and associates (2013) evaluated the effectiveness and adverse events of first-line allogeneic HSCT of HLA-matched sibling donors compared to first-line immunosuppressive therapy including cyclosporine and/or anti-thymocyte or anti-lymphocyte globulin in patients with acquired severe AA. The authors concluded that there are insufficient and biased data that do not allow any conclusions to be made about the comparative effectiveness of first-line allogeneic HSCT of an HLA-matched sibling donor and first-line treatment with cyclosporine and/or anti-thymocyte or anti-lymphocyte globulin (as first-line immunosuppressive therapy). These investigators stated that they were unable to make firm recommendations regarding the choice of intervention for treatment of acquired severe AA.
Williams and colleagues (2014) noted that randomized clinical trials in pediatric AA are rare and data to guide standards of care are scarce. Eighteen pediatric institutions formed the North American Pediatric Aplastic Anemia Consortium (NAPAAC) to foster collaborative studies in AA. The initial goal of NAPAAC was to survey the diagnostic studies and therapies utilized in AA. The survey indicated considerable variability among institutions in the diagnosis and treatment of AA. There were areas of general consensus, including the need for a bone marrow evaluation, cytogenetic and specific fluorescent in-situ hybridization assays to establish diagnosis and exclude genetic etiologies with many institutions requiring results prior to initiation of IST; uniform referral for HSCT as first line therapy if an HLA-identical sibling is identified; the use of first-line IST containing horse anti-thymocyte globulin and cyclosporine A (CSA) if an HLA-identical sibling donor is not identified; supportive care measures; and slow taper of CSA after response. Areas of controversy included the need for telomere length results prior to IST, the time after IST initiation defining a treatment failure; use of hematopoietic growth factors; the preferred rescue therapy after failure of IST; the use of specific hemoglobin and platelet levels as triggers for transfusion support; the use of prophylactic antibiotics; and follow-up monitoring after completion of treatment. The authors concluded that these initial survey results reflected heterogeneity in diagnosis and care amongst pediatric centers and emphasized the need to develop evidence-based diagnosis and treatment approaches in this rare disease.
Aplastic anemia is a disorder characterized by the presence of pancytopenia and a hypo-cellular bone marrow. Acquired pure red cell aplasia (PRCA), a part of a unique form of AA, is a rare condition of profound anemia characterized by the absence of reticulocytes and the virtual absence of erythroid precursors in the bone marrow.
An UpToDate review on “Determining eligibility for allogeneic hematopoietic cell transplantation” (Deeg and Sandmaier, 2014) states that “In general, allo-HCT may be considered in the following settings …. Nonmalignant inherited and acquired marrow disorders -- Treatment of sickle cell anemia, beta-thalassemia major, refractory Diamond-Blackfan anemia, myelodysplastic syndrome, idiopathic severe aplastic anemia, paroxysmal nocturnal hemoglobinuria, pure red cell aplasia, Fanconi anemia, amegakaryocytosis, or congenital thrombocytopenia”.
|CPT Codes / HCPCS Codes / ICD-10 Codes|
|Information in the [brackets] below has been added for clarification purposes.  Codes requiring a 7th character are represented by "+":|
|ICD-10 codes will become effective as of October 1, 2015:|
|Transplantation - Allogeneic:|
|CPT codes covered if selection criteria are met:|
|38230||Bone marrow harvesting for transplantation; allogeneic|
|38240||Hematopoietic progenitor cell (HPC); allogeneic transplantation per donor|
|86813||HLA typing; A, B or C multiple antigens|
|86817||DR/DQ, multiple antigens|
|86821||lymphocyte culture, mixed (MCL)|
|86822||lymphocyte culture, primed (PLC)|
|Other CPT codes related to the CPB:|
|38204 - 38215||Bone marrow or stem cell services/procedures|
|85004 - 85049||Blood count|
|85055||Reticulated platelet assay|
|85060||Blood smear, peripheral, interpretation by physician with written report|
|85097||Bone marrow, smear interpretation|
|86920 - 86923||Compatibility test each unit|
|HCPCS codes covered if selection criteria are met:|
|S2150||Bone marrow or blood-derived stem-cells (peripheral or umbilical), allogeneic or autologous, harvesting, transplantation, and related complications; including: pheresis and cell preparation/storage; marrow ablative therapy; drugs, supplies, hospitalization with outpatient follow-up; medical/surgical, diagnostic, emergency, and rehabilitative services; and the number of days of pre- and post-transplant care in the global definition|
|ICD-10 codes covered if selection criteria are met:|
|D59.5||Paroxysmal nocturnal hemoglobinuria [Marchiafava-Micheli]|
|D60.0 - D61.9||Aplastic anemia [severe]|
|Transplantation - Autologous:|
|CPT codes not covered for indications listed in the CPB:|
|38232||Bone marrow harvesting for transplantation; autologous|
|38241||Hematopoietic progenitor cell (HPC); autologous transplantation|